Bisoprolol Fumarate is the most selective beta-1 blocker. It has highest level of affinity for the beta-1 receptor than any other beta-blocker available up to now. It selectively blocks beta-1 adrenergic receptor in the heart and vascular smooth muscle and reduces heart rate and cardiac output resulting in decrease of arterial hypertension.
Bisoprolol Fumarate is the most selective beta-1 blocker. It has highest level of affinity for the beta-1 receptor than any other beta-blocker available up to now. It selectively blocks beta-1 adrenergic receptor in the heart and vascular smooth muscle and reduces heart rate and cardiac output resulting in decrease of arterial hypertension. Lipid metabolism can be adversely affected by beta-1 blockers, in patients with non-selective beta-blocker, but Bisoprolol does not cause any change in the cholesterol fraction including the cardioprotective HDL-cholesterol in long-term therapy.
Ancor-2.5 Tablet: Each tablet contains Bisoprolol Fumarate USP 2.5 mg.
Ancor-5 Tablet: Each tablet contains Bisoprolol Fumarate USP 5 mg.
Ancor-10 Tablet: Each tablet contains Bisoprolol Fumarate USP 10 mg.
Hypertension, angina and adjunct in stable moderate to severe heart failure
Hypertension and angina: Usually Ancor 5-10 mg once daily, max. 20 mg daily, Moderate to severe heart failure: Initially 1.25 mg once daily (in the morning) for 1 week then, if well tolerated, increased to 2.5 mg once daily for 1 week, then 3.75 mg once daily for 1 week, then 5 mg once daily for 4 weeks, then 7.5 mg once daily for 4 weeks, then Ancor 10 mg once daily; max.10 mg daily.
In patients with cardiogenic shock, overt heart failure, second or third degree A-V block, right ventricular failure secondary to pulmonary hypertension and sinus bradycardia.
Gastro-intestinal disturbances, bradycardia, hypotension, peripheral vasoconstriction, headache, fatigue, sleep disturbances, dizziness, vertigo, sexual dysfunction; thrombocytopenia; visual disturbances, alopecia may be occurred.
Monitoring of renal, hepatic, and hematopoietic function should be performed at regular intervals during long-term treatment with bisoprolol.
Bisoprolol (Ancor) should not be combined with other beta-blocking agents.
Use in pregnancy: The safety of bisoprolol during pregnancy has not been established
Use in lactation: No data is available for lactation.
Use in children: Safety and effectiveness in children have not been established.
Ancor-2.5 Tablet: Each box contains 30’s tablets in blister pack.
Ancor-5 Tablet: Each box contains 30’s tablets in blister pack.
Ancor-10 Tablet: Each box contains 10’s tablets in blister pack
Ancor-2.5 Tablet: Each tablet contains Bisoprolol Fumarate USP 2.5 mg.
Ancor-5 Tablet: Each tablet contains Bisoprolol Fumarate USP 5 mg.
Ancor-10 Tablet: Each tablet contains Bisoprolol Fumarate USP 10 mg.
Hypertension, angina and adjunct in stable moderate to severe heart failure
Hypertension and angina: Usually 5-10 mg once daily, max. 20 mg daily, Moderate to severe heart failure: Initially 1.25 mg once daily (in the morning) for 1 week then, if well tolerated, increased to 2.5 mg once daily for 1 week, then 3.75 mg once daily for 1 week, then 5 mg once daily for 4 weeks, then 7.5 mg once daily for 4 weeks, then 10 mg once daily; max.10 mg daily.
In patients with cardiogenic shock, overt heart failure, second or third degree A-V block, right ventricular failure secondary to pulmonary hypertension and sinus bradycardia.
Monitoring of renal, hepatic, and hematopoietic function should be performed at regular intervals during long-term treatment with bisoprolol.
Gastro-intestinal disturbances, bradycardia, hypotension, peripheral vasoconstriction, headache, fatigue, sleep disturbances, dizziness, vertigo, sexual dysfunction; thrombocytopenia; visual disturbances, alopecia may be occurred.
Bisoprolol should not be combined with other beta-blocking agents.
Use in pregnancy: The safety of bisoprolol during pregnancy has not been established
Use in lactation: No data is available for lactation.
Use in children: Safety and effectiveness in children have not been established.
Ancor-2.5 Tablet: Each box contains 30’s tablets in blister pack.
Ancor-5 Tablet: Each box contains 30’s tablets in blister pack.
Ancor-10 Tablet: Each box contains 10’s tablets in blister pack
FR
DE
